GlassScriptPhysician profile
Syed H Mehdi
NPI 1518931138
$6,567.14
in general payments reported to CMS, 2019-2025
22 companies · $791 in 2025
The $791 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $60.73 · 2021: $16.60 · 2022: $115 · 2023: $2,573 · 2024: $2,668 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,049 · Food and Beverage: $2,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,048.53 |
| Food and Beverage | $2,982.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,381.47 | 2023-2025 | Cascadia Interbody System, Spinejack, Optablate |
| Nuvasive, INC. | $1,832.61 | 2023 | Xlif, Tlif, Acp |
| Abbvie INC. | $667.62 | 2019-2025 | |
| Kyocera Medical Technologies, INC. | $267.78 | 2024 | |
| Medtronic, INC. | $227.48 | 2024 | Unid_pass |
| Ardelyx, INC. | $196.45 | 2023-2025 | Ibsrela |
| Globus Medical, INC. | $142.14 | 2025 | Excelsius Gps |
| Takeda Pharmaceuticals U.S.A., INC. | $130.29 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.93 | 2019-2023 | Trulance, Uceris |
| Boston Scientific Corporation | $94.73 | 2022 | |
| Madrigal Pharmaceuticals | $88.45 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $87.55 | 2024-2025 | |
| Celgene Corporation | $54.44 | 2023-2024 | Zeposia |
| Janssen Biotech, INC. | $51.34 | 2019 | |
| Pfizer INC. | $33.87 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $33.59 | 2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $33.28 | 2019 | |
| Ebi, LLC | $31.87 | 2025 | Biomet Spinalpak Non-Invasive Spine Fusion Stimulator System |
| Highridge Medical LLC | $31.32 | 2024-2025 | Biomet Ebi Bone Healing System, Biomet Spinalpak Non-Invasive Spine Fusion Stimulator System |
| Genzyme Corporation | $29.38 | 2025 | |
| Ferring Pharmaceuticals INC. | $19.12 | 2025 | Euflexxa |
| Depuy Synthes Sales INC. | $18.43 | 2025 | Monovisc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Mehdi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.